Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05075122
Title Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Martin-Luther-Universität Halle-Wittenberg
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine

Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.